- AML drugs:
	- induction:
		- cytarabine
		- daunorubicin/idarubicin

	- cytarabine (Ara-C):
		- cytosine arabinoside
		- mechanism:
			- strand termination -> inhibits DNA/RNA pol
		- metabolism: liver
		- side effects:
			- GI: mucosal inflammation, ulceration, diarrhea
			- myelosuppression
		- notes: short half life (use continuous IV)

	- daunorubicin/idarubicin
		- mechanism: intercalates DNA -> inhibits topo II -> free radicals
		- metabolism: liver
		- side effects:
			- GI: ematogenic, mucosal inflammation, diarrhea
			- myelosuppression
			- alopecia
			- cardiac toxicity

	- venetoclax:
		- BLC2 inhibitor
		- single dose

	- prevent relapse:
		- auto/allo transplant
		- maintenance

- APL drugs:
	- all-trans retinoic acid (ATRA):
	- arsenic trioxide:
	- dexamethasone: APL differentiation syndrome

- MDS drugs:
	- maturation drugs:
		- EPO + G-CSF: improves Hgb ~40%
		- darbepoetin: improves Hgb 64%
		- luspatercept: binds TGF-Î² ligands -> decreased SMAD2/3 -> erythroid maturation
			- allows transfusion independence ~40% patients
	- lenalidomide:
		- improves cytopenia
	
	- hypomethylating agents:
		- azacitidine/decitabine:
			- prolongs life, complete response 20%

- ALL drugs:
	 - induction:
	 	- prednisone
	 	- dexamethasone
	 	- vincristine
	 	- doxorubicin
	 	- cyclophosphomide
	 	- asparaginase: depletes asparagine

	 	- Sick At COD after they finish chemo = Steroids + Asparaginase + Cyclophosphomide + Oncristine + Doxorubicin 

	 - CNS therapy:
	 	- craniospinal irradiation
	 	- ithrathecal methotrexate + cytarabine
	 	- CNS = Cytarabine + Nethotrexate + Sun (irradiation)

	 - maintenance:
	 	- prednisone
	 	- mercaptopurine
	 	- methotrexate

	 	- M&Ms (mercaptopurine, methotrexate, Steroids)

	 - relapse treatment:
	 	- blinatumomab:
	 		- heavy hitter
	 		- binds CD19 + CD3 -> binds B + T cells -> T-cell lyses B-cell
	 	- CAR T

- CLL drugs:
	- regimens:
		- FCR: fludarabine, cyclophosphamide, rituximab
		- FR: fludarabine, rituximab
		- BR: bendamustine, rituximab
	- targeted:
		- ibrutinib: I-nhibits brutons tyrosine kinase
		- venetoclax: BCL2 antagonist
			- BCL2 -> inhibits cytochrome C apoptosis

		- idelalisib: blocks PI3K in BCR pathway

- lymphoma drugs:
	- DLBCL:
		- R-CHOP:
			- rituximab:
				- tumor lysis syndrome, reactivation of HBV
				- hypogammaglobulinemia
				- progressive multifocal leokoencephalopathy (PML - JC virus)
			- cyclophosphomide: myelosuppression, hemorrhagic cystitis
			- doxorubicin (hydroxydaunorubicin): myelosuppression, cardiomyopathy
			- vincristine (oncovin): neuropathy
			- prednisone:
				- SE: hyperglycemia, weight gain, agitation

		- polatuzumab-R-CHP (pola-R-CHP)
		- relapse:
			- axicabtagene ciloleucel (axi-cel) (CAR-T)

	- non-hodgkin lumphoma:
		- radiotherapy:
			- curative in early indolent lymphoma
			- adjunct for bulky disease + DLBCL

	- burkitt's lymphoma:
		- high intensity immunochemotherapy

	- follicular lymphoma:
		- radiation: curative for early
		- rituximab: low burden
		- bendamustine + CHOP: high burden
		- relapsed: axicabtagene ciloleucel

	- marginal zone lymphoma:
		- antibiotics: for H. pylori

	- mantle cell lumphoma:
		- aggressive: cytarabine + auto-SCT
			- unfit: bendamustine + rituximab


- hodgkins + T-cell lymphomas:
	- hodgkins:
		- ABVD:
			- adriaxmycin (doxorubicin): myelosuppression, cardiomyopathy
			- bleomycin: pulmonary fibrosis
			- vinblastine: neuropathy
			- dacarbazine: akylator: myelosuppression
		- if response -> drop bleomycin
		- if worse -> BEACOPP
		- radiation:
			- early stage
			- bulky disease
		- relapsed:
			- auto/allo-SCT
			- brentuximab vedotin: anti-CD30 (RS cells) + anti-microtubule
			- nivolumab: T-cells kill RS cells
		- advanced stage:
			- A+ AVD: add brentuximab veodtin, drop bleomycin
		- refractory:
			- anti-PD-1


		- paradigms:
			- A + AVD / AVBD
				- if worse -> BE A COPP
			- relapse: allo-SCT, anti-PD1, A (BV)

	- T-cell lymphomas:
		- peripheral T cell (PTCL-NOS):
			- chemotherapies
		- anaplastic large T-cell:
			- brentuximab vedotin
		- cutaneous T-cell lymphoma (mycosis fungoides):
			- topical glucocorticoids
			- UV radiation
			- topical/systemic chemotx
			- transplant
			- topical SUCT = topical Steroids UV radiation Chemo Transplant


- multiple myeloma:
	- chemotherapy:
		- HDM-AHCT
		- proteasome inhibitors:
			- bortezomib, carfilzomib, ixazomib
			- side effects: shingles risk -> add antivirals (acyclovir)

			- Zome-ib = proteasome inhibitor -> Z for zoster -> acyclovir

		- immunomodulators: kill MM cells
			- lenalidomide, pomalidomide, thalidomide
			- side effects: DVT, PE -> aspirin or anticoag
		- alkylators:
			- melphalan, cyclophosphamide, bendamustine
		- targeted:
			- daratumumab (CD38)
			- elotuzumab (CD319)
		- steroids
		- regimens:
			- steroid + PI + immunomodulator
			- steroid + akylator + immunomodulator
			- steroid + immunomodulator

			- SPI, SAI or SI  = Steroids + Immunomodulator + Akylator + Proteasome Inhibitor
	- SCT
	- radiation: for bone lesions or plasmacytoma
	- surgery: stabilize bones
	- kyphoplasty/vertebroplasty: treat compression fractures
	- bone modifiers: denosumab (RANKLi) + zoledronic acid (bisphosphonate)

	- MM = auto transplant


- myeloproliferative neoplasms:
	- CML:
		- imatinib: BCR-ABL inhibitor
			- nilotinib

	- polycythemia vera (PV):
		- therapeutic phlebotomy
		- low dose aspirin
		- cytoreduction:
			- < 40 yo: interferon alfa
			- > 40 yo: hydroxyurea: weakest chemotx -> inhibits ribonucleotide reductase

	- essential thrombocytosis (ET):
		- <60 yo, no high risk: low dose aspirin
		- >60 yo, prior TE, CV risks: low dose aspirin + hydroxyurea
			- hyroxyurea intolerant: use anagrelide or interferon alfa

	- primary myelofibrosis (PMF):
		- supportive:
			- EPO/transfusions
			- hydroxyurea
			- splenectomy/radiation
			- "supportive SETHS" = Sun + EPO + Transfusions + Hydroxurea + Splenectomy
		- active:
			- SCT
			- thalidomide + corticosteroids
			- ruxolitinib/fedratinib: JAK2 inhibitors

			- Transplant + Steroids + Immune modulators + Ji
			- PMF becomes active -> just in time compilation support = JITs = JAK2i + Immune-modulators + Transplant + Steroids



mnemonics:

leukemia:
	MDS - 3 groups - differentiate, immunomodulate, prolong life (hypomethylators), SCT
	AML - 7 + 3 (C + Dauno) -> if weak venetoclax, SCT for relapse prevention
	APL - arsenic + ATRA, APL differentiatio syndrome - steroids

	ALL - induction: Sick At COD, CNS: C-N-S, maintenance: M&Ms, relapse: bind T-cells
	CLL - OGs F'C'R: FCR, FR, BR, new kids: ibrutinib or venetoclax

lymphoma:
	non-hodgkins:
		mantle zone - strong "mantle" so cytarabine + auto-SCT, if weak: bendamustine + rituximab
		DLBCL - pol-R-CHOP, relapse: car-T
		follicular - B-CHOP, relapse: car-T
		burkitt's - high dose chemo
		marginal zone - antibiotics (H. pylori)

	hodgkins - A + AVD if bad -> BE A COPP, A = brentuximab vedotin, relapse: SCT, BV, anti-PD1
	
	T-cell:
		PTCL-NOS - chemo
		anaplastic large - brentuximab vedotin (A)
		cutaneous / mycosis fungoides - topical SUCT

multiple myeloma - SPI, SAI, or SI, bone tx, auto SCT

myeloproliferative neoplasms (MPNs):
	CML - imatinib, nilotinib
	PV - phlebotomy, aspirin, <40 -> interferon-alfa, >40 -> hydroxyurea
	ET - aspirin, >60 or risks -> hydroxyurea, interferon-alfa, or anagrelide
	PMF - supportive SETHS and active JITS


